221 related articles for article (PubMed ID: 31043468)
1. Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa.
Van TT; Minejima E; Chiu CA; Butler-Wu SM
J Clin Microbiol; 2019 Jul; 57(7):. PubMed ID: 31043468
[TBL] [Abstract][Full Text] [Related]
2. Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories.
Humphries RM; Abbott AN; Hindler JA
J Clin Microbiol; 2019 Jun; 57(6):. PubMed ID: 30971460
[TBL] [Abstract][Full Text] [Related]
3. Surveillance of Fluoroquinolone Resistance in Wisconsin: Geographic Variation and Impact of Revised CLSI Breakpoints.
Lazzerini G; Lavey SC; Fox BC; Munson E
Clin Med Res; 2022 Jun; 20(2):81-88. PubMed ID: 35086853
[No Abstract] [Full Text] [Related]
4. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.
Dudley MN; Ambrose PG; Bhavnani SM; Craig WA; Ferraro MJ; Jones RN;
Clin Infect Dis; 2013 May; 56(9):1301-9. PubMed ID: 23334813
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Hansen GT; Blondeau JM
J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
[TBL] [Abstract][Full Text] [Related]
6. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
Jones RN; Pfaller MA;
Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
Stone GG; Bradford PA; Yates K; Newell P
J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
[TBL] [Abstract][Full Text] [Related]
8. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
9. Reanalysis of cefazolin surrogate susceptibility breakpoints utilized as guidances for oral cephalosporin treatments of uncomplicated urinary tract infections: caution concerning application to cefadroxil.
Nguyen HM; Jones RN
Diagn Microbiol Infect Dis; 2020 Jul; 97(3):115053. PubMed ID: 32349909
[TBL] [Abstract][Full Text] [Related]
10.
Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Sahm DF
J Med Microbiol; 2020 Feb; 69(2):207-217. PubMed ID: 31976856
[No Abstract] [Full Text] [Related]
11. Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes.
Labreche MJ; Frei CR
Am J Health Syst Pharm; 2012 Nov; 69(21):1863-70. PubMed ID: 23111670
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Ciprofloxacin and Levofloxacin Disk Diffusion and Etest Using the 2019
Humphries RM; Hindler JA; Shaffer K; Campeau SA
J Clin Microbiol; 2019 Mar; 57(3):. PubMed ID: 30567744
[TBL] [Abstract][Full Text] [Related]
13. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
14. Resistance to oral antibiotics in 4569 Gram-negative rods isolated from urinary tract infection in children.
Calzi A; Grignolo S; Caviglia I; Calevo MG; Losurdo G; Piaggio G; Bandettini R; Castagnola E
Eur J Pediatr; 2016 Sep; 175(9):1219-1225. PubMed ID: 27558493
[TBL] [Abstract][Full Text] [Related]
15. Switching from CLSI to EUCAST XL susceptibility breakpoint: its implication in urinary tract infection in men.
Aguirre-Quiñonero A; Lecaroz Agara MC; Canut Blasco A
Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1813-1815. PubMed ID: 29936620
[No Abstract] [Full Text] [Related]
16. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.
DeRyke CA; Kuti JL; Nicolau DP
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):337-44. PubMed ID: 17350206
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.
Sahm DF; Critchley IA; Kelly LJ; Karlowsky JA; Mayfield DC; Thornsberry C; Mauriz YR; Kahn J
Antimicrob Agents Chemother; 2001 Jan; 45(1):267-74. PubMed ID: 11120976
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility profiles of Gram-negative bacilli isolated from patients with hepatobiliary infections in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2006-2010.
Toh HS; Chuang YC; Huang CC; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Ko WC; Yu KW; Liu YC; Chen YS; Tang HJ; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S18-23. PubMed ID: 22749054
[TBL] [Abstract][Full Text] [Related]
19. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
Jones RN; Beach ML; Pfaller MA
Diagn Microbiol Infect Dis; 2001 Nov; 41(3):161-3. PubMed ID: 11750171
[TBL] [Abstract][Full Text] [Related]
20. The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens.
Chen YH; Ko WC; Hsueh PR
Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):1699-704. PubMed ID: 22052606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
